Infinity BiologiX Announces Vaccine Storage Program

Vaccination development has been underway for months with nearly 40 COVID-19 vaccines going through clinical trials with promising outcomes. Frontrunners have filed for FDA review and are expected to be available for distribution for priority groups before end of 2020. However, the criticality of the next phase of the process focuses on appropriate cold-chain management, global storage, and distribution. The WHO recently reported that 2.8 million vaccines were lost in five countries due to cold chain failures.

IBX’s vaccine storage program recognizes the need for effective vaccine management practices and incorporates three integral assets to cover each step of the supply chain process. These include:

● Ultra-low Temperature Dedicated Storage Units: IBX identifies and validates dedicated storage units while also ensuring continuous temperature monitoring and unit inspection. CDC guidelines report that vaccine storage temperature requirements will range between -20°C to -86°C. IBX validated units will run this temperature gamut in a single system.

● Shipment and Sample Management: IBX also oversees that all vaccines are shipped, pre-registered, and tracked to ensure safe and timely delivery.

● Inventory and Lot Management and Specialized Distribution Logistics: IBX’s secure, web-based inventory management system integrates supply chain purchasing and ordering through distribution to health care providers and territorial health departments. It will allow complete lot management prior to distribution with specialized temporary units and logistics. This will be essential for vaccine programs requiring multi doses per subject with a few weeks spread in between each.

“IBX has been proud to provide game changing solutions during this global public health crisis. Our teams have been working around-the-clock processing over fifty thousand COVID-19 tests per day and are focused on continued scalability with anticipated higher demand due to the critical flu season,” stated Robin Grimwood, IBX President and COO. He continued, “The scale at which this vaccine will be distributed requires incredible knowledge and expertise. We have partnered with key suppliers to fully automate processes and deliver fast results without compromising accuracy or precision. Now, we will also manage the variability in storage temperature needs for COVID-19 vaccines and control all steps in the supply chain and distribution. With our state-of-the-art scientific approach and experience, we feel confident in safely storing and distributing approved vaccines across the country.”

New York-Presbyterian recently selected IBX to store and manage the distribution of their COVID-19 vaccine inventory when these become available. IBX plans to also support a number of other health providers’ vaccine inventories and expects to make other announcements shortly.

For ultra-low temperature storage, IBX has partnered with the best-in-class freezer manufacturer, Stirling Ultracold as part of its vaccine program. The company provides the only commercially available freezers to run the ULT gamut from -20°C to -86°C in a single system that is required by the top vaccine contenders and a critical asset in safely storing and administering COVID-19 vaccines.

“The work IBX has done to prepare their local communities for COVID-19 vaccine distribution is truly remarkable,” commented Dusty Tenney, Stirling Ultracold CEO. He continued, “Pairing their sophisticated inventory lot management system with a vast collection of ULT freezer solutions means these critical vaccines will be well managed from receipt through inoculation and cataloged for multi-dose requirements. This white-glove vaccine logistics and storages-service is truly innovative and we are proud to be part of the solution.”

Russell Hager, IBX Executive VP of Strategic Operations concluded, “IBX strives to be on the front-end of problem-solving to reduce the continued risks and challenges the world has encountered with the COVID-19 pandemic. We stand shoulder to shoulder in this battle with the front-line essential workforce, health care providers and the scientists who have worked tirelessly in developing a vaccine. We are eager to soon be able to support these providers as they distribute the vaccine to millions and bring us closer to ending this global pandemic.”

About Infinity BiologiX

Infinity BiologiX (IBX) is a market-disrupting next-generation central laboratory supporting academia, government, and industry. IBX provides global sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas. As a leader in biomaterials, IBX provides support to the development of diagnostics, therapeutics, and research in the genomics, precision, and regenerative medicine arenas. IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020

For more information, visit www.ibx.bio

View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005378/en/